Literature DB >> 14675923

Interstitial laser coagulation versus transurethral resection of the prostate for benign prostatic enlargement--a prospective randomized study.

Fredrik Liedberg1, Lars Adell, Gunnar Hagberg, Inga-Britt Palmqvist.   

Abstract

OBJECTIVE: Interstitial laser coagulation (ILC) of the prostate is a minimally invasive method for treating symptomatic benign prostatic enlargement (BPE). We performed a prospective randomized study to compare the clinical outcomes of ILC and transurethral resection of the prostate (TURP).
MATERIAL AND METHODS: Between December 1997 and February 2000, 38 patients with moderate-to-severe symptomatic BPE were included in the study. Seven were subsequently excluded due to intercurrent disease or protocol violation and the remaining 31 were randomized to either TURP (n=11) or ILC (n=20). A suprapubic tube was inserted in all ILC-treated patients, and ILC was performed as an outpatient procedure when feasible. Data were recorded preoperatively and at 3-month and 1-year follow-up. The assessment parameters were International Prostate Symptom Score (IPSS), uroflow, prostate volume determined by means of transrectal ultrasound and postvoid residue.
RESULTS: At 1-year follow-up, uroflowmetry indicated a more pronounced increase in peak urinary flow rate (Qmax) in the TURP patients than in the ILC subjects (p<0.02). Differences in postvoid residue, IPSS and prostate volume between the two treatments could not be evaluated due to the small number of patients in each group. Postoperative urinary tract infections occurred in 13 ILC patients but in only one TURP subject, and catheterization was done for 24 days after ILC and for 2 days after TURP. The study was ended prematurely due to the prolonged postoperative catheterization and the high rate of urinary tract infections in the ILC patients.
CONCLUSIONS: At 1-year follow-up, the increase in Qmax was smaller in the ILC subjects than in the TURP patients. The ILC subjects had comparatively more postoperative urinary tract infections and more prolonged postoperative catheterization than the TURP patients.

Entities:  

Mesh:

Year:  2003        PMID: 14675923     DOI: 10.1080/00365590310001773

Source DB:  PubMed          Journal:  Scand J Urol Nephrol        ISSN: 0036-5599


  12 in total

1.  2010 Update: Guidelines for the management of benign prostatic hyperplasia.

Authors:  J Curtis Nickel; Carlos E Méndez-Probst; Thomas F Whelan; Ryan F Paterson; Hassan Razvi
Journal:  Can Urol Assoc J       Date:  2010-10       Impact factor: 1.862

Review 2.  New laser treatment approaches for benign prostatic hyperplasia.

Authors:  Nathaniel M Fried
Journal:  Curr Urol Rep       Date:  2007-01       Impact factor: 3.092

3.  [Therapy of benign prostate syndrome (BPS): guidelines of the German Urologists (DGU)].

Authors:  R Berges; K Dreikorn; K Höfner; S Madersbacher; M C Michel; R Muschter; M Oelke; O Reich; W Rulf; C Tschuschke; U Tunn
Journal:  Urologe A       Date:  2009-12       Impact factor: 0.639

4.  [Benign prostatic syndrome (BPS). Ablative treatments].

Authors:  O Reich; M Seitz; C Gratzke; B Schlenker; A Bachmann; C Stief
Journal:  Urologe A       Date:  2006-06       Impact factor: 0.639

Review 5.  Urethral stricture following endoscopic prostate surgery: a systematic review and meta-analysis of prospective, randomized trials.

Authors:  Giacomo Maria Pirola; Daniele Castellani; Ee Jean Lim; Marcelo Langer Wroclawski; Dong Le Quy Nguyen; Marilena Gubbiotti; Emanuele Rubilotta; Vinson Wai-Shun Chan; Mariela Corrales; Esther García Rojo; Thomas R W Herrmann; Jeremy Yuen-Chun Teoh; Vineet Gauhar
Journal:  World J Urol       Date:  2022-02-13       Impact factor: 4.226

6.  Energy delivery systems for treatment of benign prostatic hyperplasia: an evidence-based analysis.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2006-08-01

7.  Medical therapy versus surgery and minimally invasive surgical therapies for lower urinary tract symptoms and benign prostatic hyperplasia: what makes better economic sense?

Authors:  Mark D Stovsky; Katherine Rhee; David Hartke
Journal:  Curr Urol Rep       Date:  2007-07       Impact factor: 3.092

8.  Bladder neck stenosis after transurethral prostate surgery: a systematic review and meta-analysis.

Authors:  Daniele Castellani; Marcelo Langer Wroclawski; Giacomo Maria Pirola; Vineet Gauhar; Emanuele Rubilotta; Vinson Wai-Shun Chan; Bryan Kwun-Chung Cheng; Marilena Gubbiotti; Andrea Benedetto Galosi; Thomas R W Herrmann; Jeremy Yuen-Chun Teoh
Journal:  World J Urol       Date:  2021-05-11       Impact factor: 4.226

9.  Is the minimally invasive treatment as good as transurethral resection for benign prostatic hyperplasia?

Authors:  Emerson Luís Zani; Nelson Rodrigues Netto
Journal:  Int Urol Nephrol       Date:  2007-03-02       Impact factor: 2.266

10.  Efficacy and safety profile of a novel technique, ThuLEP (Thulium laser enucleation of the prostate) for the treatment of benign prostate hypertrophy. Our experience on 148 patients.

Authors:  Fabrizio Iacono; Domenico Prezioso; Giovanni Di Lauro; Giuseppe Romeo; Antonio Ruffo; Ester Illiano; Bruno Amato
Journal:  BMC Surg       Date:  2012-11-15       Impact factor: 2.102

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.